Lack of efficacy of estradiol for depression in postmenopausal women: A randomized, controlled trial

被引:181
作者
Morrison, MF
Kallan, MJ
Ten Have, T
Katz, I
Tweedy, K
Battistini, M
机构
[1] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA
[4] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA
关键词
estradiol; depressive disorder; postmenopausal;
D O I
10.1016/j.biopsych.2003.08.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Estrogen has been considered as a potential antidepressant in postmenopausal women. Our goal was to study whether estrogen therapy is effective in treating depressive disorders in older postmenopausal women and to determine whether progestins are associated with a deterioration of mood. Methods: After 2 weeks of single-blind placebo treatment in 87 patients, 57 were randomly assigned to receive 8 weeks of treatment with estradiol (.1 mg/day; n = 31) or placebo (n = 26). All patients were then treated with medroxyprogesterone 10 mg/day for 2 weeks combined with the study patch. Depressive symptoms were rated with the 21-item Hamilton Depression and Center for Epidemiologic Studies Depression scales. Results. A clinically significant antidepressant effect of estradiol was excluded after 8 weeks of estradiol treatment. The estradiol group and placebo group improved in depressive symptoms at a similar rate based on the Hamilton Depression Scale (40% decreases in depression for estradiol vs. 44% for placebo). No significant increase in depressive symptoms was demonstrated with the use of progestins; however, positive affect decreased slightly with the use of combined estradiol-medroxyprogesterone compared with medroxyprogesterone alone (5.8%, p = .027). Conclusions: Estradiol cannot be considered as an effective treatment in postmenopausal women with mild to moderate depression.
引用
收藏
页码:406 / 412
页数:7
相关论文
共 60 条
[21]   Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge? [J].
Joffe, H ;
Cohen, LS .
BIOLOGICAL PSYCHIATRY, 1998, 44 (09) :798-811
[22]  
Judd LL, 1996, AM J PSYCHIAT, V153, P1411
[23]   Delineating the longitudinal structure of depressive illness: Beyond clinical subtypes and duration thresholds [J].
Judd, LL ;
Akiskal, HS .
PHARMACOPSYCHIATRY, 2000, 33 (01) :3-7
[24]   IMIPRAMINE - EFFECT OF OVARIAN-STEROIDS ON MODIFICATIONS IN SEROTONIN RECEPTOR-BINDING [J].
KENDALL, DA ;
STANCEL, GM ;
ENNA, SJ .
SCIENCE, 1981, 211 (4487) :1183-1185
[25]   THE FACTORIAL GENERALITY OF BRIEF POSITIVE AND NEGATIVE AFFECT MEASURES [J].
LAWTON, MP ;
KLEBAN, MH ;
DEAN, J ;
RAJAGOPAL, D ;
PARMELEE, PA .
JOURNALS OF GERONTOLOGY, 1992, 47 (04) :P228-P237
[26]   Epidemiology of depression in the elderly [J].
Lepine, JP ;
Bouchez, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 :S7-S12
[27]  
LEVINE J, 1986, PSYCHOPHARMACOL BULL, V22, P343
[28]   CUMULATIVE ILLNESS RATING SCALE [J].
LINN, BS ;
LINN, MW ;
GUREL, L .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1968, 16 (05) :622-&
[29]  
Little RJ, 1999, STAT MED, V18, P2465, DOI 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2465::AID-SIM269>3.0.CO
[30]  
2-2